These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27329288)

  • 1. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
    Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
    Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
    Tang X; Zou W; Peng P; Bai Y
    Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of lenalidomide in chronic lymphocytic leukemia].
    Lei W; Zhou KS; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
    Badoux XC; Keating MJ; Wen S; Wierda WG; O'Brien SM; Faderl S; Sargent R; Burger JA; Ferrajoli A
    J Clin Oncol; 2013 Feb; 31(5):584-91. PubMed ID: 23270003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
    Chavez JC; Piris-Villaespesa M; Dalia S; Powers J; Turba E; Nodzon L; Komrokji R; Sokol L; Locke FL; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Res; 2016 Aug; 47():78-83. PubMed ID: 27285853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
    Mauro FR; Carella AM; Molica S; Paoloni F; Liberati AM; Zaja F; Belsito V; Cortellezzi A; Rizzi R; Tosi P; Spriano M; Ferretti A; Nanni M; Marinelli M; De Propris MS; Orlando SM; Vignetti M; Cuneo A; Guarini AR; Foà R
    Leuk Lymphoma; 2017 Jul; 58(7):1640-1647. PubMed ID: 27881039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
    Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
    Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
    Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Ujjani C; Wang H; Skarbnik A; Trivedi N; Ramzi P; Khan N; Cheson BD
    Blood Adv; 2018 Apr; 2(7):762-768. PubMed ID: 29610115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
    J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    Maurer C; Pflug N; Bahlo J; Kluth S; Rhein C; Cramer P; Gross-Ophoff C; Langerbeins P; Fink AM; Eichhorst B; Kreuzer KA; Fischer N; Tausch E; Stilgenbauer S; Böttcher S; Döhner H; Kneba M; Dreyling M; Binder M; Hallek M; Wendtner CM; Bergmann M; Fischer K;
    Eur J Haematol; 2016 Sep; 97(3):253-60. PubMed ID: 26643449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
    Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.